Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that non-adherence to medication in the Prostate Cancer Prevention Trial was associated with increased all-cause mortality unrelated to prostate cancer.

In this study, Paljeong-san pharmacopuncture reduced dihydrotestosterone levels and inhibited prostate tissue proliferation in a rat model of benign prostatic hyperplasia.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This study found that Finnish men using 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had improved disease-specific survival compared to non-users, suggesting potential benefits of the treatment.

This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.

This article discusses the potential role of dutasteride in prostate cancer prevention, examining its effects on risk, but does not report new clinical findings.

Among a Han Chinese cohort, this study found that a higher genetic risk score was linked to increased susceptibility to BPH, larger prostate size, reduced effectiveness of 5ARI treatment, and a higher risk of undergoing TURP.

This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.

This consensus summary suggests that 5-alpha reductase inhibitors have clear benefits for benign prostatic hyperplasia, but their impact on prostate cancer prevention is still debated.

This review discusses the potential of plant-derived phytochemicals as alternatives to 5-alpha-Reductase inhibitors in treating prostate cancer, highlighting possible benefits like reduced side effects, but it reports no new findings.

This review discusses the prevalence and treatment of benign prostatic hyperplasia and reports no new findings; it emphasizes considering side effects and comorbidities in therapy choices.

This randomized, placebo-controlled trial reported that USPlus PRO saw palmetto extract significantly improved lower urinary tract symptoms, including voiding, incomplete emptying, and weak stream, as well as sexual function in males over 12 weeks, while maintaining a favorable safety profile.

This study found that finasteride and its combination with terazosin significantly reduced PSA levels in patients with benign prostatic hyperplasia, whereas terazosin alone showed no clinically significant effect.

This dissertation found that finasteride reduced prostate volume by 6.3% and total serum PSA by 10.51% in young patients over one year.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

This study reports that finasteride is effective in treating persistent hematuria associated with benign prostatic hyperplasia.

This study found that among male Han Chinese, a higher polygenic risk score was linked to increased risk and poorer treatment outcomes for benign prostatic hyperplasia.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

This study found that 60% of examined prostate tumors had new somatic substitutions in the SRD5A2 gene, affecting enzyme activity and potentially influencing prostate cancer progression.

This study found that screening for prostate cancer did not significantly reduce prostate cancer-specific mortality in a meta-analysis of five randomized controlled trials, although one trial reported a benefit in a specific age subgroup.

This study reported that treatment with tamsulosin and finasteride significantly improved symptoms and reduced the risk of clinical progression in patients with benign prostatic hyperplasia.

In this study, finasteride alone or combined with terazosin significantly reduced PSA levels in men with BPH, while terazosin alone did not affect PSA levels.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This study found that bilateral orchiectomy allows most transgender women to stop anti-androgen medications, with 91.7% discontinuing them post-surgery and 25% reducing estrogen use.

This review examines the current research on chemopreventive agents for prostate cancer, highlighting that while no definitive strategies have been confirmed, substances like finasteride, selenium, and vitamin E show promise in reducing risk.

This review discusses the role of vitamins, micronutrients, and diets in prostate cancer prevention and reports no new clinical results, emphasizing a shift towards focusing on diet over supplements.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

This study highlights the need for a comprehensive andrological assessment at diagnosis, including semen and hormonal analysis, to guide fertility preservation strategies, and found that post-orchidectomy semen samples showed improved DNA integrity for assisted reproductive technologies.